Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

APYX vs AEYE vs ALKT vs SSKN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
APYX
Apyx Medical Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$149M
5Y Perf.-64.9%
AEYE
AudioEye, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$100M
5Y Perf.-68.0%
ALKT
Alkami Technology, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$1.87B
5Y Perf.-63.5%
SSKN
STRATA Skin Sciences, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-98.9%

APYX vs AEYE vs ALKT vs SSKN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
APYX logoAPYX
AEYE logoAEYE
ALKT logoALKT
SSKN logoSSKN
IndustryMedical - DevicesSoftware - ApplicationSoftware - ApplicationMedical - Devices
Market Cap$149M$100M$1.87B$7M
Revenue (TTM)$56M$40M$472M$31M
Net Income (TTM)$-9M$-3M$-50M$-11M
Gross Margin38.1%78.3%57.4%57.8%
Operating Margin-7.7%-7.9%-9.3%-33.3%
Forward P/E21.7x
Total Debt$39M$721K$354M$16M
Cash & Equiv.$32M$5M$63M$7M

APYX vs AEYE vs ALKT vs SSKNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

APYX
AEYE
ALKT
SSKN
StockApr 21May 26Return
Apyx Medical Corpor… (APYX)10035.1-64.9%
AudioEye, Inc. (AEYE)10032.0-68.0%
Alkami Technology, … (ALKT)10036.5-63.5%
STRATA Skin Science… (SSKN)1001.1-98.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: APYX vs AEYE vs ALKT vs SSKN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Apyx Medical Corporation is the stronger pick specifically for recent price momentum and sentiment. AEYE also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
APYX
Apyx Medical Corporation
The Momentum Pick

APYX is the #2 pick in this set and the best alternative if momentum is your priority.

  • +184.8% vs SSKN's -93.3%
Best for: momentum
AEYE
AudioEye, Inc.
The Long-Run Compounder

AEYE is the clearest fit if your priority is long-term compounding.

  • 102.2% 10Y total return vs ALKT's -59.5%
  • -7.6% margin vs SSKN's -35.6%
Best for: long-term compounding
ALKT
Alkami Technology, Inc.
The Income Pick

ALKT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 1.30
  • Rev growth 32.9%, EPS growth -12.2%, 3Y rev CAGR 29.5%
  • Lower volatility, beta 1.30, Low D/E 97.7%, current ratio 2.09x
  • Beta 1.30, current ratio 2.09x
Best for: income & stability and growth exposure
SSKN
STRATA Skin Sciences, Inc.
The Lower-Volatility Pick

SSKN lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthALKT logoALKT32.9% revenue growth vs SSKN's 0.6%
Quality / MarginsAEYE logoAEYE-7.6% margin vs SSKN's -35.6%
Stability / SafetyALKT logoALKTBeta 1.30 vs AEYE's 2.29
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)APYX logoAPYX+184.8% vs SSKN's -93.3%
Efficiency (ROA)ALKT logoALKT-5.9% ROA vs SSKN's -35.9%, ROIC -8.6% vs -38.9%

APYX vs AEYE vs ALKT vs SSKN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

APYXApyx Medical Corporation
FY 2025
OEM
100.0%$8M
AEYEAudioEye, Inc.
FY 2024
Enterprise
100.0%$15M
ALKTAlkami Technology, Inc.
FY 2025
SaaS Subscription Services
95.0%$422M
Implementation Services
2.8%$13M
Service, Other
2.1%$9M
SSKNSTRATA Skin Sciences, Inc.
FY 2024
Dermatology Recurring Procedures
63.1%$21M
Dermatology Procedures Equipment
36.9%$12M

APYX vs AEYE vs ALKT vs SSKN — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAPYXLAGGINGAEYE

Income & Cash Flow (Last 12 Months)

APYX leads this category, winning 3 of 6 comparable metrics.

ALKT is the larger business by revenue, generating $472M annually — 15.2x SSKN's $31M. AEYE is the more profitable business, keeping -7.6% of every revenue dollar as net income compared to SSKN's -35.6%. On growth, APYX holds the edge at +31.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
RevenueTrailing 12 months$56M$40M$472M$31M
EBITDAEarnings before interest/tax-$4M-$504,000-$12M-$5M
Net IncomeAfter-tax profit-$9M-$3M-$50M-$11M
Free Cash FlowCash after capex-$9M$2M$44M-$4M
Gross MarginGross profit ÷ Revenue+38.1%+78.3%+57.4%+57.8%
Operating MarginEBIT ÷ Revenue-7.7%-7.9%-9.3%-33.3%
Net MarginNet income ÷ Revenue-16.4%-7.6%-10.6%-35.6%
FCF MarginFCF ÷ Revenue-16.1%+5.5%+9.4%-11.3%
Rev. Growth (YoY)Latest quarter vs prior year+31.7%+7.9%+28.9%-21.2%
EPS Growth (YoY)Latest quarter vs prior year+58.3%+29.0%-22.7%-5.9%
APYX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

SSKN leads this category, winning 2 of 3 comparable metrics.
MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
Market CapShares × price$149M$100M$1.9B$7M
Enterprise ValueMkt cap + debt − cash$157M$96M$2.2B$16M
Trailing P/EPrice ÷ TTM EPS-13.19x-32.36x-37.89x-0.67x
Forward P/EPrice ÷ next-FY EPS est.21.69x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue2.82x2.49x4.20x0.20x
Price / BookPrice ÷ Book value/share10.12x20.91x5.00x1.34x
Price / FCFMarket cap ÷ FCF45.09x
SSKN leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

Evenly matched — AEYE and ALKT each lead in 4 of 9 comparable metrics.

ALKT delivers a -14.0% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-8 for SSKN. AEYE carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to SSKN's 3.31x. On the Piotroski fundamental quality scale (0–9), APYX scores 4/9 vs ALKT's 3/9, reflecting mixed financial health.

MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
ROE (TTM)Return on equity-88.5%-47.8%-14.0%-8.4%
ROA (TTM)Return on assets-14.9%-9.5%-5.9%-35.9%
ROICReturn on invested capital-22.1%-42.4%-8.6%-38.9%
ROCEReturn on capital employed-11.8%-17.7%-9.3%-36.0%
Piotroski ScoreFundamental quality 0–94434
Debt / EquityFinancial leverage2.65x0.15x0.98x3.31x
Net DebtTotal debt minus cash$8M-$5M$290M$9M
Cash & Equiv.Liquid assets$32M$5M$63M$7M
Total DebtShort + long-term debt$39M$721,000$354M$16M
Interest CoverageEBIT ÷ Interest expense-0.97x-2.79x-3.73x-4.63x
Evenly matched — AEYE and ALKT each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ALKT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKT five years ago would be worth $4,510 today (with dividends reinvested), compared to $109 for SSKN. Over the past 12 months, APYX leads with a +184.8% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors ALKT at 12.2% vs SSKN's -74.5% — a key indicator of consistent wealth creation.

MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
YTD ReturnYear-to-date+1.7%-18.7%-23.1%-86.2%
1-Year ReturnPast 12 months+184.8%-27.9%-37.8%-93.3%
3-Year ReturnCumulative with dividends+2.3%+20.6%+41.1%-98.3%
5-Year ReturnCumulative with dividends-62.9%-60.2%-54.9%-98.9%
10-Year ReturnCumulative with dividends-45.0%+102.2%-59.5%-99.6%
CAGR (3Y)Annualised 3-year return+0.8%+6.4%+12.2%-74.5%
ALKT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — APYX and SSKN each lead in 1 of 2 comparable metrics.

SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APYX currently trades 79.1% from its 52-week high vs SSKN's 4.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
Beta (5Y)Sensitivity to S&P 5001.96x2.29x1.30x-0.24x
52-Week HighHighest price in past year$4.50$16.39$31.66$3.86
52-Week LowLowest price in past year$1.08$5.31$14.11$0.11
% of 52W HighCurrent price vs 52-week peak+79.1%+49.4%+55.1%+4.5%
RSI (14)Momentum oscillator 0–10028.661.350.941.6
Avg Volume (50D)Average daily shares traded162K194K1.9M14K
Evenly matched — APYX and SSKN each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: APYX as "Buy", ALKT as "Buy". Consensus price targets imply 68.5% upside for APYX (target: $6) vs 26.2% for ALKT (target: $22).

MetricAPYX logoAPYXApyx Medical Corp…AEYE logoAEYEAudioEye, Inc.ALKT logoALKTAlkami Technology…SSKN logoSSKNSTRATA Skin Scien…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$6.00$22.00
# AnalystsCovering analysts912
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises11
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

APYX leads in 1 of 6 categories (Income & Cash Flow). SSKN leads in 1 (Valuation Metrics). 2 tied.

Best OverallApyx Medical Corporation (APYX)Leads 1 of 6 categories
Loading custom metrics...

APYX vs AEYE vs ALKT vs SSKN: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is APYX or AEYE or ALKT or SSKN a better buy right now?

For growth investors, Alkami Technology, Inc.

(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). Analysts rate Apyx Medical Corporation (APYX) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — APYX or AEYE or ALKT or SSKN?

Over the past 5 years, Alkami Technology, Inc.

(ALKT) delivered a total return of -54. 9%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — APYX or AEYE or ALKT or SSKN?

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately -1038% more volatile than SSKN relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — APYX or AEYE or ALKT or SSKN?

By revenue growth (latest reported year), Alkami Technology, Inc.

(ALKT) is pulling ahead at 32. 9% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: Apyx Medical Corporation grew EPS 59. 1% year-over-year, compared to -12. 2% for Alkami Technology, Inc.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — APYX or AEYE or ALKT or SSKN?

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is APYX or AEYE or ALKT or SSKN more undervalued right now?

Analyst consensus price targets imply the most upside for APYX: 68.

5% to $6. 00.

07

Which pays a better dividend — APYX or AEYE or ALKT or SSKN?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is APYX or AEYE or ALKT or SSKN better for a retirement portfolio?

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Apyx Medical Corporation (APYX) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, APYX: -45. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between APYX and AEYE and ALKT and SSKN?

These companies operate in different sectors (APYX (Healthcare) and AEYE (Technology) and ALKT (Technology) and SSKN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: APYX is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; SSKN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

APYX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 15%
  • Gross Margin > 22%
Run This Screen
Stocks Like

AEYE

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 46%
Run This Screen
Stocks Like

ALKT

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 34%
Run This Screen
Stocks Like

SSKN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 34%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform APYX and AEYE and ALKT and SSKN on the metrics below

Revenue Growth>
%
(APYX: 31.7% · AEYE: 7.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.